IBDEI2F9 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,38689,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,38689,1,2,0)
 ;;=2^90688
 ;;^UTILITY(U,$J,358.3,38689,1,3,0)
 ;;=3^FLU VACCINE MULTI DOSE SYR (Flulaval)
 ;;^UTILITY(U,$J,358.3,38690,0)
 ;;=90682^^151^1984^14^^^^1
 ;;^UTILITY(U,$J,358.3,38690,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,38690,1,2,0)
 ;;=2^90682
 ;;^UTILITY(U,$J,358.3,38690,1,3,0)
 ;;=3^FLUBLOK (RIV4)
 ;;^UTILITY(U,$J,358.3,38691,0)
 ;;=90653^^151^1984^13^^^^1
 ;;^UTILITY(U,$J,358.3,38691,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,38691,1,2,0)
 ;;=2^90653
 ;;^UTILITY(U,$J,358.3,38691,1,3,0)
 ;;=3^FLU VACCINE SINGLE DOSE SYR (Fluad)
 ;;^UTILITY(U,$J,358.3,38692,0)
 ;;=B18.2^^152^1985^38
 ;;^UTILITY(U,$J,358.3,38692,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38692,1,3,0)
 ;;=3^Hepatitis C,Chr
 ;;^UTILITY(U,$J,358.3,38692,1,4,0)
 ;;=4^B18.2
 ;;^UTILITY(U,$J,358.3,38692,2)
 ;;=^5000548
 ;;^UTILITY(U,$J,358.3,38693,0)
 ;;=E11.9^^152^1985^23
 ;;^UTILITY(U,$J,358.3,38693,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38693,1,3,0)
 ;;=3^Diabetes Type 2
 ;;^UTILITY(U,$J,358.3,38693,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,38693,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,38694,0)
 ;;=E11.40^^152^1985^21
 ;;^UTILITY(U,$J,358.3,38694,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38694,1,3,0)
 ;;=3^DM Type 2 w/ Neuropathy
 ;;^UTILITY(U,$J,358.3,38694,1,4,0)
 ;;=4^E11.40
 ;;^UTILITY(U,$J,358.3,38694,2)
 ;;=^5002644
 ;;^UTILITY(U,$J,358.3,38695,0)
 ;;=E78.2^^152^1985^39
 ;;^UTILITY(U,$J,358.3,38695,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38695,1,3,0)
 ;;=3^Hyperlipidemia,Mixed
 ;;^UTILITY(U,$J,358.3,38695,1,4,0)
 ;;=4^E78.2
 ;;^UTILITY(U,$J,358.3,38695,2)
 ;;=^78424
 ;;^UTILITY(U,$J,358.3,38696,0)
 ;;=E78.5^^152^1985^40
 ;;^UTILITY(U,$J,358.3,38696,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38696,1,3,0)
 ;;=3^Hyperlipidemia,Unspec
 ;;^UTILITY(U,$J,358.3,38696,1,4,0)
 ;;=4^E78.5
 ;;^UTILITY(U,$J,358.3,38696,2)
 ;;=^5002969
 ;;^UTILITY(U,$J,358.3,38697,0)
 ;;=E66.3^^152^1985^57
 ;;^UTILITY(U,$J,358.3,38697,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38697,1,3,0)
 ;;=3^Overweight
 ;;^UTILITY(U,$J,358.3,38697,1,4,0)
 ;;=4^E66.3
 ;;^UTILITY(U,$J,358.3,38697,2)
 ;;=^5002830
 ;;^UTILITY(U,$J,358.3,38698,0)
 ;;=F17.200^^152^1985^50
 ;;^UTILITY(U,$J,358.3,38698,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38698,1,3,0)
 ;;=3^Nicotine Dependence,Unspec
 ;;^UTILITY(U,$J,358.3,38698,1,4,0)
 ;;=4^F17.200
 ;;^UTILITY(U,$J,358.3,38698,2)
 ;;=^5003360
 ;;^UTILITY(U,$J,358.3,38699,0)
 ;;=G43.909^^152^1985^48
 ;;^UTILITY(U,$J,358.3,38699,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38699,1,3,0)
 ;;=3^Migraine,Unspec
 ;;^UTILITY(U,$J,358.3,38699,1,4,0)
 ;;=4^G43.909
 ;;^UTILITY(U,$J,358.3,38699,2)
 ;;=^5003909
 ;;^UTILITY(U,$J,358.3,38700,0)
 ;;=H91.93^^152^1985^34
 ;;^UTILITY(U,$J,358.3,38700,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38700,1,3,0)
 ;;=3^Hearing Loss,Bilateral
 ;;^UTILITY(U,$J,358.3,38700,1,4,0)
 ;;=4^H91.93
 ;;^UTILITY(U,$J,358.3,38700,2)
 ;;=^5006944
 ;;^UTILITY(U,$J,358.3,38701,0)
 ;;=I10.^^152^1985^41
 ;;^UTILITY(U,$J,358.3,38701,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38701,1,3,0)
 ;;=3^Hypertension
 ;;^UTILITY(U,$J,358.3,38701,1,4,0)
 ;;=4^I10.
 ;;^UTILITY(U,$J,358.3,38701,2)
 ;;=^5007062
 ;;^UTILITY(U,$J,358.3,38702,0)
 ;;=I50.9^^152^1985^17
 ;;^UTILITY(U,$J,358.3,38702,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38702,1,3,0)
 ;;=3^Congestive Heart Failure,Unspec
